Telix Pharmaceuticals Ltd
ASX:TLX
Telix Pharmaceuticals Ltd
ASX:TLX
Price:
9.05
AUD
1.91%
Market Closed
Market Cap:
AU$3.1B
Income Statement
Earnings Waterfall
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Income Statement
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Currency: AUD
| Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
5
|
11
|
|
| Revenue |
3
N/A
|
5
+59%
|
7
+25%
|
8
+17%
|
29
+278%
|
104
+261%
|
357
+244%
|
326
-9%
|
521
+60%
|
508
-3%
|
662
+30%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
(3)
|
(2)
|
(2)
|
(3)
|
(12)
|
(42)
|
(134)
|
(122)
|
(199)
|
(194)
|
(305)
|
|
| Gross Profit |
1
N/A
|
3
+487%
|
5
+42%
|
5
+11%
|
16
+227%
|
62
+273%
|
223
+261%
|
204
-8%
|
322
+58%
|
314
-3%
|
357
+14%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(32)
|
(39)
|
(56)
|
(82)
|
(133)
|
(120)
|
(249)
|
(192)
|
(267)
|
(262)
|
(329)
|
|
| Selling, General & Administrative |
(19)
|
(24)
|
(32)
|
(47)
|
(79)
|
(56)
|
(178)
|
(87)
|
(227)
|
(128)
|
(168)
|
|
| Research & Development |
(22)
|
(23)
|
(28)
|
(34)
|
(45)
|
(53)
|
(87)
|
(84)
|
(154)
|
(126)
|
(153)
|
|
| Depreciation & Amortization |
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
12
|
14
|
9
|
4
|
(3)
|
(6)
|
21
|
(22)
|
114
|
(7)
|
(8)
|
|
| Operating Income |
(32)
N/A
|
(36)
-12%
|
(52)
-45%
|
(77)
-49%
|
(116)
-51%
|
(59)
+49%
|
(27)
+55%
|
11
N/A
|
55
+385%
|
52
-7%
|
28
-46%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
(7)
|
(11)
|
(6)
|
2
|
3
|
(1)
|
(5)
|
(0)
|
1
|
14
|
12
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(6)
|
(11)
|
(5)
|
|
| Total Other Income |
(0)
|
(1)
|
(3)
|
(5)
|
(6)
|
(4)
|
(9)
|
(8)
|
(13)
|
(19)
|
(27)
|
|
| Pre-Tax Income |
(39)
N/A
|
(48)
-24%
|
(61)
-28%
|
(80)
-32%
|
(119)
-48%
|
(64)
+46%
|
(40)
+37%
|
2
N/A
|
38
+1 811%
|
36
-5%
|
9
-75%
|
|
| Net Income | ||||||||||||
| Tax Provision |
3
|
3
|
2
|
(0)
|
(0)
|
(4)
|
(7)
|
1
|
1
|
(4)
|
2
|
|
| Income from Continuing Operations |
(36)
|
(45)
|
(59)
|
(81)
|
(119)
|
(67)
|
(48)
|
3
|
39
|
32
|
11
|
|
| Net Income (Common) |
(36)
N/A
|
(45)
-25%
|
(59)
-32%
|
(81)
-36%
|
(119)
-48%
|
(67)
+43%
|
(48)
+30%
|
3
N/A
|
39
+1 058%
|
32
-17%
|
11
-66%
|
|
| EPS (Diluted) |
-0.14
N/A
|
-0.17
-21%
|
-0.22
-29%
|
-0.29
-32%
|
-0.4
-38%
|
-0.22
+45%
|
-0.15
+32%
|
0.01
N/A
|
0.12
+1 100%
|
0.09
-25%
|
0.03
-67%
|
|
Switch to:
Switch to:
See Also
Discover More
